Ginsenoside Rg3 potentiates cisplatin antitumor activity while mitigating nephrotoxicity through SIRT1-mediated suppression of the NLRP3 inflammasome
Jinghui Zhai, Yueming Zhang, Jiawei Gong, Li Fu, Sixi Zhang · 2026
Read Ginsenoside Rg3 potentiates cisplatin antitumor activity while mitigating nephrotoxicity through SIRT1-mediated suppression of the NLRP3 inflammasome by Jinghui Zhai, Yueming Zhang, Jiawei Gong, Li Fu, Sixi Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13221113.txt.
Description
Jinghui Zhai and co-authors test a ginseng compound alongside cisplatin in a 2026 lung cancer study. Cisplatin works well against tumors, yet it harms kidneys and tumors often resist it. Ginsenoside Rg3, drawn from ginseng, has shown anticancer effects and possible protection for healthy tissue.
In cell and mouse experiments, the pairing killed more lung cancer cells and slowed tumor growth better than either agent alone. Rg3 also eased kidney injury by calming an inflammatory complex through the SIRT1 pathway, an effect reversed when SIRT1 was blocked. Transporter changes may explain both kidney protection and reduced drug resistance. The compound looks promising as a chemotherapy partner.
Catalog record
| CREATOR | Jinghui Zhai, Yueming Zhang, Jiawei Gong, Li Fu, Sixi Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |